• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
  

PubMed=1358431
Nakagawa M., Schneider E., Dixon K.H., Horton J.K., Kelley K., Morrow C., Cowan K.H.
Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
Cancer Res. 52:6175-6181(1992)

PubMed=7664272
Yang C.-H.J., Horton J.K., Cowan K.H., Schneider E.
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Cancer Res. 55:4004-4009(1995)

PubMed=9865745
Rabindran S.K., He H.-Y., Singh M., Brown E., Collins K.I., Annable T., Greenberger L.M.
Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.
Cancer Res. 58:5850-5858(1998)

PubMed=11559526
Honjo Y., Hrycyna C.A., Yan Q.-W., Medina-Perez W.Y., Robey R.W., van de Laar A., Litman T., Dean M., Bates S.E.
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Cancer Res. 61:6635-6639(2001)